Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JYLAMVO vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of severe, active rheumatoid arthritis in adults,Treatment of polyarticular-course juvenile idiopathic arthritis in children,Treatment of severe psoriasis in adults
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Methotrexate is primarily metabolized in the liver to polyglutamated forms, which are retained intracellularly. It undergoes hepatic metabolism via aldehyde oxidase and xanthine oxidase. Renal excretion is the major elimination route.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
Volume of distribution is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability is 60-75% due to first-pass metabolism; absolute bioavailability is 70%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment is recommended for patients with mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl 15-29 m L/min), reduce dose to 20 mg twice daily. For end-stage renal disease (Cr Cl <15 m L/min) or on dialysis, not recommended due to lack of data.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate hepatic impairment (Child-Pugh B), reduce dose to 20 mg twice daily. For severe hepatic impairment (Child-Pugh C), not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy in pediatric patients have not been established; no recommended dosage.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment required based on age alone; monitor for increased risk of adverse events (e.g., myelosuppression, infections) as elderly patients may have decreased organ function and comorbidities.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
JYLAMVO can cause severe or fatal toxicities including hepatotoxicity, myelosuppression, pulmonary fibrosis, and renal failure. It is contraindicated in pregnancy (teratogenic) and in nursing mothers. Fatal toxicity has been reported with concomitant NSAID use. Monitoring for toxicity and appropriate dosing adjustments are required.
None.
Hepatotoxicity (monitor liver function), myelosuppression (monitor CBC), pulmonary toxicity (interstitial pneumonitis), renal toxicity (monitor renal function), gastrointestinal toxicity, neurotoxicity, infections, and tumor lysis syndrome. Corticosteroids or other immunosuppressants may increase risk of infection.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to methotrexate, severe hepatic impairment, severe renal impairment, severe anemia, leukopenia, thrombocytopenia, pregnancy, breastfeeding, alcoholism, pre-existing immunodeficiency syndromes, and concurrent use of NSAIDs in patients with renal impairment.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions are known. Administer without regard to meals. Maintain adequate hydration.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS defects) and spontaneous abortion. Second and third trimester use may cause fetal growth restriction, developmental delay, and potential methotrexate syndrome. Use effective contraception during and for at least 3 months after treatment.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Contraindicated during breastfeeding. Methotrexate is excreted into breast milk in low concentrations (M/P ratio 0.6-1.1), but due to potential for serious adverse effects (immunosuppression, neutropenia, developmental toxicity) in the nursing infant, breastfeeding is not recommended. Discontinue breastfeeding or avoid JYLAMVO.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Not applicable. JYLAMVO is contraindicated in pregnancy. No dose adjustments exist as it should not be used during pregnancy. Discontinue immediately if pregnancy occurs.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
JYLAMVO (amivantamab) is a bispecific EGFR-MET antibody for EGFR exon 20 insertion mutation-positive NSCLC. Monitor for infusion-related reactions (premedicate with antihistamines, antipyretics, and corticosteroids). Assess for interstitial lung disease (ILD) prior to each dose; withhold for suspected ILD. Check serum albumin and electrolytes before treatment; hypoalbuminemia increases risk of toxicities. Advise use of sunscreen and sun protective measures due to photosensitivity risk.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
JYLAMVO is given as an intravenous infusion over 2-4 hours, typically every 2 weeks after an initial loading dose.,You may experience infusion reactions; symptoms include fever, chills, nausea, or shortness of breath. Tell your nurse immediately if these occur.,This drug can cause lung inflammation (ILD); report any new or worsening cough, chest pain, or difficulty breathing.,Avoid prolonged sun exposure; use broad-spectrum sunscreen (SPF 30+) and wear protective clothing.,Your doctor will monitor your blood counts and kidney function regularly during treatment.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JYLAMVO vs AURLUMYN, answered by our medical review team.
JYLAMVO is a Antineoplastic Agent that works by JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JYLAMVO and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JYLAMVO is: Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JYLAMVO and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JYLAMVO is classified as Category C. JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.